Atossa Genetics Inc (NASDAQ:ATOS), announced that it will issue financial results and corporate developments for the First Quarter ended March 31, 2014, following the market close on Wednesday May, 14, 2014. Atossa Genetics Inc (NASDAQ:ATOS), weekly performance is 13.61%. On last trading day company shares ended up $8.20. Analysts mean target price for the company is $8.75. Atossa Genetics Inc (NASDAQ:ATOS), distance from 50-day simple moving average (SMA50) is -15.61%.
On May 07, 2014, Relypsa Inc (NASDAQ:RLYP), a biopharmaceutical company, reported financial results for the first quarter ended March 31, 2014. Net loss for the first quarter 2014 was $16.1 million, or $0.54 per share, compared to $26.3 million, or $84.61 per share, for the comparable period in 2013. Relypsa Inc (NASDAQ:RLYP), advanced 6.12% in last trading session and ended the day on $22.70. RLYP, return on assets is -145.30%. Relypsa Inc (NASDAQ:RLYP), quarterly performance is -41.07%.
NeoStem Inc (NASDAQ:NBS), a leader in the emerging cellular therapy industry, announced that the Company has signed an exclusive license agreement with China-based Cellular Biomedicine Group (OTCQB:CBMG) (“CBMG”) to begin a Phase 2 clinical trial in patients with late stage liver cancer. NeoStem Inc (NASDAQ:NBS), shares moved up 5.20% in last trading session and was closed at $5.26, while trading in range of $4.96 – 5.48. NeoStem Inc (NASDAQ:NBS), year to date (YTD) performance is -22.87%.
On May 08, 2014, TearLab Corp (NASDAQ:TEAR), reported its consolidated financial results for the first quarter ended March 31, 2014. For the three months ended March 31, 2014, TearLab’s net revenues were $4.2 million, up 70% from $2.5 million for the same period in 2013. A total of 254 orders for TearLab systems were booked in the first quarter. Of those, 201 systems were under the Company’s Masters Multi Unit Program, 40 were through its minimum use access programs, 6 were direct purchases and 7 were purchased outside of the U.S. TearLab Corp (NASDAQ:TEAR), ended the last trading day at $4.37. Company weekly volatility is calculated as 9.62% and price to cash ratio as 3.88. TearLab Corp (NASDAQ:TEAR), showed a positive weekly performance of 6.33%.